Albiglutide
A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.
GSK · Phase 3 · Completed · Enrollment 507
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| albiglutide | n/r | n/r | n/r | n/r |
| sitagliptin | n/r | n/r | n/r | n/r |
Not shown
- albiglutide: endpoint not reported
- sitagliptin: endpoint not reported